

36. An adjuvant composition as claimed in claim 32, wherein the immunostimulant is monophosphoryl lipid A or a derivative thereof.

37. An adjuvant composition as claimed in claim 36, wherein the derivative of monophosphoryl lipid A is 3-de-O-acylated monophosphoryl lipid A.

~~38. An adjuvant composition as claimed in claim 32, wherein the immunostimulant is CpG containing oligonucleotide.~~

~~39. A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, characterised in that the metallic salt particle is substantially free of other antigen, and b) an antigen.~~

40. A process for the manufacture of a vaccine composition as claimed in claim 39, characterised in that the antigen is adsorbed onto a metallic salt particle.

41. A process as claimed in claims 39, wherein the antigen is selected from the group comprising: antigens derived from Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, IgE peptides, Der p1, pollen related antigens; or Tumor associated antigens (TAA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRh (GnRH), CEA, PSA, KSA, or PRAME.

~~42. A vaccine composition comprising an adjuvant composition according to claims 32 to 38, additionally comprising an antigen.~~

43. A vaccine produced according to the process claimed in any one of claims 39 to 41.

44. A vaccine comprising a saponin adsorbed onto a metallic salt particle wherein the vaccine comprises an antigen, characterised in that the metallic salt particle is substantially free of other antigen.

45. A vaccine according to claim 44, wherein the saponin is QS21.

46. A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle.

Sub. D3
Cont
B

09807657 041604

47. A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of monophosphoryl lipid A, or derivative thereof.

48. A vaccine composition as claimed in claims 46 or 47, wherein the metallic salt present in the first and second complexes are identical.

49. A vaccine composition as claimed in claims 46 or 47, wherein the second complex comprises a plurality of sub-complexes, each sub-complex comprising a different antigen adsorbed onto a metallic particle.

50. A vaccine composition as claimed in any one of claims 44 to 47, wherein the metallic salt is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or beryllium.

51. A vaccine as claimed in claim 50 wherein the metallic salt is a phosphate or hydroxide.

52. A vaccine composition as claimed in claim 51 wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

53. A vaccine composition as claimed in claim 42, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

54. A vaccine composition as claimed in claim 43, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

55. A vaccine composition as claimed in claim 45, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

56. A vaccine composition as claimed in claim 46, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

57. A vaccine composition as claimed in claim 47, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

58. A vaccine composition as claimed in claim 48, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

59. A vaccine composition as claimed in claim 49, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

09807657-041604

Alt
B'

60. A vaccine composition as claimed in claim 50, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

61. A vaccine composition as claimed in claim 51, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

62. A vaccine composition as claimed in claim 52, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

~~63. A vaccine composition as claimed in claim 42, wherein the immunostimulant is CpG.~~

64. A vaccine composition as claimed in claim 43, wherein the immunostimulant is CpG.

65. A vaccine composition as claimed in claim 44, wherein the immunostimulant is CpG.

66. A vaccine composition as claimed in claim 45, wherein the immunostimulant is CpG.

67. A vaccine composition as claimed in claim 46, wherein the immunostimulant is CpG.

68. A vaccine composition as claimed in claim 47, wherein the immunostimulant is CpG.

69. A vaccine composition as claimed in claim 48, wherein the immunostimulant is CpG.

70. A vaccine composition as claimed in claim 49, wherein the immunostimulant is CpG.

~~71. A vaccine composition as claimed in claim 42, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.~~

~~72. A vaccine composition as claimed in claim 43, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus,~~

Cont
B'

09807657 041501

Sub D⁴

Intl. App. No.: PC1/99/07764

Docket No. B45158

Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

73. A vaccine composition as claimed in claim 44, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

74. A vaccine composition as claimed in claim 45, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

75. A vaccine composition as claimed in claim 46, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

76. A vaccine composition as claimed in claim 47, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus,

Cont
B'

09807657, 041501

Sub-D4

Intl. App. No.: PCT/99/07764
Docket No. B45158

Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

77. A vaccine composition as claimed in claim 48, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

78. A vaccine composition as claimed in claim 49, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

79. A vaccine composition as claimed in claim 50, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

80. A vaccine composition as claimed in claim 51, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus,

Cont
B'

09807657 041500

Sub. 04

Intl. App. No.: PCT/JP99/07764
Docket No. B45158

Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

81. A vaccine composition as claimed in claim 52, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

82. A vaccine composition as claimed in claim 71, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

83. A vaccine composition as claimed in claim 72, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

84. A vaccine composition as claimed in claim 73, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

85. A vaccine composition as claimed in claim 74, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

86. A vaccine composition as claimed in claim 75, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

87. A vaccine composition as claimed in claim 76, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

88. A vaccine composition as claimed in claim 77, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

89. A vaccine composition as claimed in claim 78, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

90. A vaccine composition as claimed in claim 79, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

Cont
B1

09807657,041604

Sub. 04

Intl. App. No.: PCT/JP99/07764
Docket No. B45158

91. A vaccine composition as claimed in claim 80, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.
92. A vaccine composition as claimed in claim 81, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.
93. A vaccine composition as claimed in claim 71, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
94. A vaccine composition as claimed in claim 72, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
95. A vaccine composition as claimed in claim 73, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
96. A vaccine composition as claimed in claim 74, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
97. A vaccine composition as claimed in claim 75, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
98. A vaccine composition as claimed in claim 76, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
99. A vaccine composition as claimed in claim 77, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
100. A vaccine composition as claimed in claim 78, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
101. A vaccine composition as claimed in claim 79, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
102. A vaccine composition as claimed in claim 80, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
103. A vaccine composition as claimed in claim 81, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
104. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 71.
105. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 72.

Sub DP

Cont
B'

09807657.04158.1

106. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 73.

107. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 74.

108. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 75.

109. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 76.

110. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 77.

111. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 78.

112. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 79.

113. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 80.

114. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 81.

115. A kit comprising two containers, one container having monophosphoryl lipid A, or derivative thereof, adsorbed onto a metallic salt; and the second container having antigen adsorbed onto a metallic salt.

Cont
B)

09807657-041601